Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:

Is the benefit of Abemacicib compromised in those that require dose reductions?

A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.

Clinicians should utilize dose modifications when necessary to maximize adherence.”

Additional information.
Source: Matthew Goetz/LinkedIn